(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
2 days till quarter result
(amc 2024-05-06)
Expected move: +/- 6.45%
0.87% $ 22.05
@ $22.05
Emitido: 14 feb 2024 @ 15:38
Retorno: 0.00%
Señal anterior: feb 13 - 15:50
Señal anterior:
Retorno: 4.26 %
Live Chart Being Loaded With Signals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD)...
Stats | |
---|---|
Volumen de hoy | 583 893 |
Volumen promedio | 1.10M |
Capitalización de mercado | 1.87B |
EPS | $0 ( 2024-02-27 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.40 |
ATR14 | $0.0150 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-07 | Metzger Michael A | Buy | 214 500 | Stock Options (Right to buy) |
2024-02-07 | Metzger Michael A | Buy | 39 000 | Common Stock |
2024-02-07 | Metzger Michael A | Buy | 107 250 | Common Stock |
2024-02-07 | Goldan Keith A. | Buy | 70 000 | Stock Options (Right to buy) |
2024-02-07 | Goldan Keith A. | Buy | 11 700 | Common Stock |
INSIDER POWER |
---|
46.07 |
Last 97 transactions |
Buy: 2 711 593 | Sell: 1 085 664 |
Volumen Correlación
Syndax Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
IDLB | 0.85 |
NWS | 0.846 |
NWSA | 0.832 |
ARVN | 0.824 |
BAFN | 0.824 |
CENTA | 0.821 |
ISDX | 0.821 |
CVCY | 0.817 |
ADRE | 0.817 |
CIGI | 0.812 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Syndax Pharmaceuticals Correlación - Moneda/Commodity
Syndax Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-12 000.00 (0.00 %) |
EPS: | $-2.98 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-12 000.00 (0.00 %) |
EPS: | $-2.98 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-454 000 (0.00 %) |
EPS: | $-2.37 |
FY | 2021 |
Ingresos: | $139.71M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $0.480 |
Financial Reports:
No articles found.
Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico